Galena Biopharma Hires Joseph Lasaga as Vice President, Business Development and Alliance Management
January 20 2015 - 7:05AM
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
treatments that address major medical needs across the full
spectrum of cancer care, today announced it has hired Joseph Lasaga
as Vice President, Business Development and Alliance Management,
reporting to the President and CEO.
"Joe is an experienced and accomplished business development
professional, and we are excited to have him join the Galena team,"
said Mark W. Schwartz, Ph.D., President and CEO. "In addition to
significant transaction experience and a global network of industry
contacts, Joe brings a strong background in research, drug
development, and alliance management. As our commercial
programs and development pipeline continue to mature, we will seek
opportunities to extend the value of our individual assets as well
as Galena as a whole."
Mr. Joseph Lasaga has more than 17 years of experience in the
biotechnology and pharmaceutical industry in the areas of research
and development, business development, alliance management and
product strategy. Prior to joining Galena, Mr. Lasaga
spent four years at Nektar Therapeutics, most recently as Senior
Director, Business Development where he led the successful
execution of several transactions for the company and managed
several key partnerships. He was primarily responsible for
leading global business development and licensing activities
for Nektar's oncology portfolio, which included early stage
pre-clinical and late stage clinical programs. Between 1998-2010,
Mr. Lasaga worked at Rigel Pharmaceuticals where he held roles
of increasing responsibility across various departments departing
as Associate Director of Business Development. He led
and participated in many buy-side and sell-side asset
transactions adding significant value to the organization
during his tenure there. Mr. Lasaga received his Masters
of Business Administration in Marketing from San Francisco State
University and his Bachelor of Science in Molecular Biology with a
minor in Chemistry from San Jose State University.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical
company developing and commercializing innovative, targeted
oncology therapeutics that address major medical needs across the
full spectrum of cancer care. Galena's development
portfolio ranges from mid- to late-stage clinical assets, including
a robust immunotherapy program led by NeuVax™ (nelipepimut-S)
currently in an international, Phase 3 clinical trial. The
Company's commercial drugs include Abstral® (fentanyl) Sublingual
Tablets and Zuplenz® (ondansetron) Oral Soluble Film. Collectively,
Galena's clinical and commercial strategy focuses on identifying
and advancing therapeutic opportunities to improve cancer
care, from direct treatment of the disease to the reduction of
its debilitating side-effects. For more information,
visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the plans and objectives of management for future
operations and business development, progress of the
commercialization of Abstral® and development of Galena's product
candidates, including patient enrollment in our clinical trials, as
well as statements about our expectations, plans and prospects.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those identified under
"Risk Factors" in Galena's Annual Report on Form 10-K for the year
ended December 31, 2013 and most recent Quarterly Reports on Form
10-Q filed with the SEC. Actual results may differ materially from
those contemplated by these forward-looking statements. Galena does
not undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this press release.
Abstral and NeuVax are trademarks of Galena Biopharma,
Inc. All other trademarks are the property of their respective
owners.
CONTACT: Remy Bernarda
VP, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024